As per enclosed letter.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Divis Laboratories reported strong full-year results with standalone PAT growing 18% to ₹2,607 crore from ₹2,209 crore. Consolidated PAT rose 17.2% to ₹2,568 crore from ₹2,191 crore. Revenue from operations grew 13% standalone (₹10,388 crore) and 12.8% consolidated (₹10,560 crore). The company recorded ₹74 crore as an exceptional item due to the impact of new Labour Codes. Foreign exchange gains boosted Other Income significantly to ₹506 crore standalone vs ₹352 crore in FY2024-25. The Board recommended a dividend of ₹30 per share (1500%) consistent with the prior year. Capital work-in-progress more than doubled to ₹2,113 crore indicating major expansion underway. Statutory auditors issued unmodified opinions on both standalone and consolidated results.
The 17-18% PAT growth demonstrates solid operational performance, though below 20% threshold. The ₹74 crore exceptional charge and higher depreciation from expansion may pressure near-term margins. Strong forex gains boosted bottom-line but are volatile. Ongoing capacity expansion signals confidence in future demand.